Regional variation and cost implications of prescribed extended half‐life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia
Sign Up to like & getrecommendations! Published in 2019 at "Haemophilia"
DOI: 10.1111/hae.13758
Abstract: Extended half‐life (EHL) factor VIII (FVIII) and IX (FIX) products are intended to decrease the burden of prophylaxis for patients with haemophilia A or B. Whether these newer concentrates have led to meaningful clinical practice… read more here.
Keywords: extended half; haemophilia regional; regional variation; factor ... See more keywords